HomeS49 • FRA
add
Supernus Pharmaceuticals Inc
Previous close
€30.80
Day range
€31.20 - €31.20
Year range
€21.80 - €32.40
Market cap
1.87B USD
Avg Volume
11.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | 168.32M | 24.17% |
Operating expense | 132.20M | 0.71% |
Net income | 19.92M | 2,496.63% |
Net profit margin | 11.83 | 2,039.34% |
Earnings per share | 0.67 | 36.14% |
EBITDA | 38.93M | 891.14% |
Effective tax rate | 24.28% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 347.19M | 128.93% |
Total assets | 1.32B | 1.76% |
Total liabilities | 358.38M | -3.97% |
Total equity | 957.45M | — |
Shares outstanding | 55.11M | — |
Price to book | 1.77 | — |
Return on assets | 3.48% | — |
Return on capital | 4.63% | — |
Cash Flow
Net change in cash
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Net income | 19.92M | 2,496.63% |
Cash from operations | 35.62M | 288.75% |
Cash from investing | -48.59M | -180.59% |
Cash from financing | 1.66M | 100.35% |
Net change in cash | -11.31M | 97.41% |
Free cash flow | 34.91M | -91.36% |
About
Founded
2005
Headquarters
Website
Employees
652